Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity

Cold Spring Harbor Perspectives in Biology

Volumn 11, Issue 3, 2019, Pages

  Alspach, Elise ^a   Lussier, Danielle M ^a   Schreiber, Robert D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR;

ANIMAL; ANTIGEN PRESENTING CELL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; METABOLISM; NEOPLASM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGEN-PRESENTING CELLS; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MOLECULAR STRUCTURE; NEOPLASMS; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION;

EID: 85063661054     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a028480     Document Type: Article

References (139)

1. Abed NS, Chace JH, Fleming AL, Cowdery JS. 1994. Interferon-γ regulation of B lymphocyte differentiation: Activation of B cells is a prerequisite for IFN-γ-mediated inhibition of B cell differentiation. Cell Immunol 153: 356–366.
2. + T cells. Nat Immunol 3: 549–557.
3. Agnello D, Lankford CSR, Bream J, Morinobu A, Gadina M, O’Shea JJ, Frucht DM. 2003. Cytokines and transcription factors that regulate T helper cell differentiation: New players and new insights. J Clin Immunol 23: 147–161.
4. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, et al. 1999. SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98: 597–608.
5. Arakawa T, Hsu YR, Parker CG, Lai PH. 1986. Role of poly-cationic C-terminal portion in the structure and activity of recombinant human interferon-γ. J Biol Chem 261: 8534–8539.
6. Bach EA, Szabo SJ, Dighe AS, Ashkenazi A, Aguet M, Murphy KM, Schreiber RD. 1995. Ligand-induced autoregu-lation of IFN-γ receptor β chain expression in T helper cell subsets. Science 270: 1215–1218.
7. Bach EA, Tanner JW, Marsters S, Ashkenazi A, Aguet M, Shaw AS, Schreiber RD. 1996. Ligand-induced assembly and activation of the γ interferon receptor in intact cells. Mol Cell Biol 16: 3214–3221.
8. Bach EA, Aguet M, Schreiber RD. 1997. The IFN γ receptor: A paradigm for cytokine receptor signaling. Annu Rev Immunol 15: 563–591.
9. Bradley LM, Dalton DK, Croft M. 1996. A direct role for IFN-γ in regulation of Th1 cell development. J Immunol 157: 1350–1358.
10. Buchmeier NA, Schreiber RD. 1985. Requirement of endogenous interferon-γ production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci 82: 7404– 7408.
11. Caux C, Ramos RN, Prendergast GC, Bendriss-Vermare N, Ménétrier-Caux C. 2016. A milestone review on how macrophages affect tumor growth. Cancer Res 76: 6439–6442.
12. Chang CH, Hammer J, Loh JE, Fodor WL, Flavell RA. 1992. The activation of major histocompatibility complex class I genes by interferon regulatory factor-1 (IRF-1). Immu-nogenetics 35: 378–384.
13. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY. 1997. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 17: 5328–5337.
14. Cresswell P. 1994. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 12: 259–293.
15. Darnell JE, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415–1421.
16. Dighe AS, Farrar MA, Schreiber RD. 1993. Inhibition of cellular responsiveness to interferon-γ (IFNγ) induced by overexpression of inactive forms of the IFNγ receptor. J Biol Chem 268: 10645–10653.
17. Dighe AS, Richards E, Old LJ, Schreiber RD. 1994. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. Immunity 1: 447–456.
18. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8: 793–800.
19. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. 2012. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482: 405–409.
20. Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, Bugg CE. 1991. Three-dimensional structure of recombinant human interferon-γ. Science 252: 698–702.
21. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Mi-sawa H, et al. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387: 921–924.
22. Farrar MA, Schreiber RD. 1993. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 11: 571–611.
23. Farrar MA, Fernandez-Luna J, Schreiber RD. 1991. Identification of two regions within the cytoplasmic domain of the human interferon-γ receptor required for function. J Biol Chem 266: 19626–19635.
24. Farrar MA, Campbell JD, Schreiber RD. 1992. Identification of a functionally important sequence in the C terminus of the interferon-γ receptor. Proc Natl Acad Sci 89: 11706– 11710.
25. Fountoulakis M, Lahm HW, Maris A, Friedlein A, Manne-berg M, Stueber D, Garotta G. 1991. A 25-kDa stretch of the extracellular domain of the human interferon γ receptor is required for full ligand binding capacity. J Biol Chem 266: 14970-14977.
26. Fountoulakis M, Zulauf M, Lustig A, Garotta G. 1992. Stoichiometry of interaction between interferon γ and its receptor. Eur J Biochem 208: 781–787.
27. Gaczynska M, Rock KL, Spies T, Goldberg AL. 1994. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc Natl Acad Sci 91: 9213–9217.
28. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, et al. 2017. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23: 551.
29. Gil MP, Bohn E, O’Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW, Schreiber RD. 2001. Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci 98: 6680–6685.
30. Gray PW, Goeddel DV. 1982. Structure of the human immune interferon gene. Nature 298: 859–863.
31. Gray PW, Goeddel DV. 1983. Cloning and expression of murine immune interferon cDNA. Proc Natl Acad Sci 80: 5842–5846.
32. Greenlund AC, Schreiber RD, Goeddel DV, Pennica D. 1993. Interferon-γ induces receptor dimerization in solution and on cells. J Biol Chem 268: 18103–18110.
33. Greenlund AC, Farrar MA, Viviano BL, Schreiber RD. 1994. Ligand-induced IFN γ receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J 13: 1591–1600.
34. Greenlund AC, Morales MO, Viviano BL, Yan H, Krolewski J, Schreiber RD. 1995. Stat recruitment by tyrosine-phos-phorylated cytokine receptors: An ordered reversible affinity-driven process. Immunity 2: 677–687.
35. Guillerey C, Smyth MJ. 2016. NK cells and cancer immunoediting. Curr Top Microbiol Immunol 395: 115–145.
36. + T cells responding to infection. J Immunol 174: 6791–6802.
37. Harrington LE, Mangan PR, Weaver CT. 2006. Expanding the effector CD4 T-cell repertoire: The Th17 lineage. Curr Opin Immunol 18: 349–356.
38. Hershey GK, Schreiber RD. 1989. Biosynthetic analysis of the human interferon-γ receptor. Identification of N-linked glycosylation intermediates. J Biol Chem 264: 11981–11988.
39. Hibino Y, Mariano TM, Kumar CS, Kozak CA, Pestka S. 1991. Expression and reconstitution of a biologically active mouse interferon γ receptor in hamster cells. Chromosomal location of an accessory factor. J Biol Chem 266: 6948-6951.
40. Hogrefe HH, McPhie P, Bekisz JB, Enterline JC, Dyer D, Webb DS, Gerrard TL, Zoon KC. 1989. Amino terminus is essential to the structural integrity of recombinant human interferon-γ. J Biol Chem 264: 12179–12186.
41. Hoshino K, Tsutsui H, Kawai T, Takeda K, Nakanishi K, Takeda Y, Akira S. 1999. Cutting edge: Generation of IL-18 receptor-deficient mice: Evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 162: 5041–5044.
42. Igarashi K, Garotta G, Ozmen L, Ziemiecki A, Wilks AF, Harpur AG, Larner AC, Finbloom DS. 1994. Interferon-γ induces tyrosine phosphorylation of interferon-γ recep-recep-tor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. J Biol Chem 269: 14333– 14336. tor
43. Ikeda H, Old LJ, Schreiber RD. 2002. The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13: 95–109.
44. Jarpe MA, Johnson HM. 1990. Topology of receptor binding domains of mouse IFN-γ. J Immunol 145: 3304–3309.
45. 0 end of HuIFNγ cDNA. J Immunol 129: 2357–2359.
46. Jung V, Rashidbaigi A, Jones C, Tischfield JA, Shows TB, Pestka S. 1987. Human chromosomes 6 and 21 are required for sensitivity to human interferon γ. Proc Natl Acad Sci 84: 4151–4155.
47. Jurado A, Carballido J, Griffel H, Hochkeppel HK, Wetzel GD. 1989. The immunomodulatory effects of interferon-γ on mature B-lymphocyte responses. Experientia 45: 521–526.
48. Kane LP, Lin J, Weiss A. 2000. Signal transduction by the TCR for antigen. Curr Opin Immunol 12: 242–249.
49. Kaplan DH, Greenlund AC, Tanner JW, Shaw AS, Schreiber RD. 1996. Identification of an interferon-γ receptor α chain sequence required for JAK-1 binding. J Biol Chem 271: 9–12.
50. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immu-nocompetent mice. Proc Natl Acad Sci 95: 7556–7561.
51. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903–907.
52. Kotenko SV, Izotova LS, Pollack BP, Mariano TM, Donnelly RJ, Muthukumaran G, Cook JR, Garotta G, Silvennoinen O, Ihle JN. 1995. Interaction between the components of the interferon γ receptor complex. J Biol Chem 270: 20915–20921.
53. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al. 2016. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7: 10501.
54. Leach DR, Krummel MF, Allison JP. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734–1736.
55. Leinikki PO, Calderon J, Luquette MH, Schreiber RD. 1987. Reduced receptor binding by a human interferon-γ fragment lacking 11 carboxyl-terminal amino acids. J Immunol 139: 3360–3366.
56. Lewis CE, Pollard JW. 2006. Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605–612.
57. Li MO, Wan YY, Sanjabi S, Robertson AKL, Flavell RA. 2006. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 24: 99–146.
58. Liew FY, Li Y, Millott S. 1990a. Tumor necrosis factor-α synergizes with IFN-γ in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 145: 4306–4310.
59. L -arginine. J Immunol 144: 4794–4797.
60. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, Nguyen BV, Gadina M, Sher A, Paul WE, et al. 2001. T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells. Proc Natl Acad Sci 98: 15137–15142.
61. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, Shuai K. 1998. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci 95: 10626–10631.
62. MacKie RM, Reid R, Junor B. 2003. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 348: 567–568.
63. Mah AY, Cooper MA. 2016. Metabolic regulation of natural killer cell IFN-γ production. Crit Rev Immunol 36: 131– 147.
64. Mandal M, Bandyopadhyay D, Goepfert TM, Kumar R. 1998. Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene 16: 217–225.
65. Maraskovsky E, Chen WF, Shortman K. 1989. IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T cells. J Immunol 143: 1210–1214.
66. Marine JC, Topham DJ, McKay C, Wang D, Parganas E, Stravopodis D, Yoshimura A, Ihle JN. 1999. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98: 609–616.
67. Marsters SA, Pennica D, Bach E, Schreiber RD, Ashkenazi A. 1995. Interferon γ signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. Proc Natl Acad Sci 92: 5401–5405.
68. Matsuda JL, Zhang Q, Ndonye R, Richardson SK, Howell AR, Gapin L. 2006. T-bet concomitantly controls migration, survival, and effector functions during the development of Vα14i NKT cells. Blood 107: 2797–2805.
69. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, et al. 2012. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482: 400–404.
70. Müller-Hermelink N, Braumüller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haub-ner R, Sander CA, et al. 2008. TNFR1 signaling and IFN-γ signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13: 507–518.
71. Murakami M, Narazaki M, Hibi M, Yawata H, Yasukawa K, Hamaguchi M, Taga T, Kishimoto T. 1991. Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci 88: 11349–11353.
72. Nacy CA, Fortier AH, Meltzer MS, Buchmeier NA, Schreiber RD. 1985. Macrophage activation to kill Leishmania major: Activation of macrophages for intracellular destruction of amastigotes can be induced by both recombinant interferon-γ and non-interferon lymphokines. J Immunol 135: 3505–3511.
73. Nagarajan NA, Kronenberg M. 2007. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol 178: 2706–2713.
74. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et al. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924–929.
75. Naka T, Tsutsui H, Fujimoto M, Kawazoe Y, Kohzaki H, Morita Y, Nakagawa R, Narazaki M, Adachi K, Yoshimoto T, et al. 2001. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-γ and IL-4 signaling in vivo. Immunity 14: 535–545.
76. Naylor SL, Sakaguchi AY, Shows TB, Law ML, Goeddel DV, Gray PW. 1983. Human immune interferon gene is located on chromosome 12. J Exp Med 157: 1020–1027.
77. Naylor SL, Gray PW, Lalley PA. 1984. Mouse immune interferon (IFN-γ) gene is on chromosome 10. Somat Cell Mol Genet 10: 531–534.
78. * Negishi H, Taniguchi T, Yanai H. 2017. The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a028423.
79. Nguyen H, Ramana CV, Bayes J, Stark GR. 2001. Roles of phosphatidylinositol 3-kinase in interferon-γ-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J Biol Chem 276: 33361–33368.
80. Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hun-dal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, et al. 2017. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res 5: 106–117.
81. Noy R, Pollard JW. 2014. Tumor-associated macrophages: From mechanisms to therapy. Immunity 41: 49–61.
82. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K. 1995. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378: 88–91.
83. Oriss TB, McCarthy SA, Morel BF, Campana MA, Morel PA. 1997. Crossregulation between T helper cell (Th)1 and Th2: Inhibition of Th2 proliferation by IFN-γ involves interference with IL-1. J Immunol Baltim Md 1950 158: 3666-3672.
84. O’Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MWL, et al. 2012. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 209: 1869–1882.
85. Ouchi T, Lee SW, Ouchi M, Aaronson SA, Horvath CM. 2000. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-γ target genes. Proc Natl Acad Sci 97: 5208–5213.
86. Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Bru-nazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, et al. 2017. Interferon-γ drives Treg fragility to promote anti-tumor immunity. Cell 169: 1130–1141.e11.
87. Pamer E, Cresswell P. 1998. Mechanisms of MHC class I– restricted antigen processing. Annu Rev Immunol 16: 323–358.
88. Pan J, Zhang M, Wang J, Wang Q, Xia D, Sun W, Zhang L, Yu H, Liu Y, Cao X. 2004. Interferon-γ is an autocrine mediator for dendritic cell maturation. Immunol Lett 94: 141–151.
89. Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252–264.
90. Penix L, Weaver WM, Pang Y, Young HA, Wilson CB. 1993. Two essential regulatory elements in the human interferon γ promoter confer activation specific expression in T cells. J Exp Med 178: 1483–1496.
91. Penix LA, Sweetser MT, Weaver WM, Hoeffler JP, Kerppola TK, Wilson CB. 1996. The proximal regulatory element of the interferon-γ promoter mediates selective expression in T cells. J Biol Chem 271: 31964–31972.
92. H 1 cells. Science 269: 245–247.
93. Pfizenmaier K, Wiegmann K, Scheurich P, Krönke M, Merlin G, Aguet M, Knowles BB, Ucer U. 1988. High affinity human IFN-γ-binding capacity is encoded by a single receptor gene located in proximity to c-ros on human chromosome region 6q16 to 6q22. J Immunol 141: 856– 860.
94. Ramana CV, Gil MP, Schreiber RD, Stark GR. 2002. Stat1-dependent and-independent pathways in IFN-γ-depen-dent signaling. Trends Immunol 23: 96–101.
95. Reis LF, Harada H, Wolchok JD, Taniguchi T, Vilcek J. 1992. Critical role of a common transcription factor, IRF-1, in the regulation of IFN-β and IFN-inducible genes. EMBO J 11: 185–193.
96. Roy SK, Wachira SJ, Weihua X, Hu J, Kalvakolanu DV. 2000. CCAAT/enhancer-binding protein-β regulates interferon-induced transcription through a novel element. J Biol Chem 275: 12626–12632.
97. Russell JK, Hayes MP, Carter JM, Torres BA, Dunn BM, Russell SW, Johnson HM. 1986. Epitope and functional specificity of monoclonal antibodies to mouse interferon-γ: The synthetic peptide approach. J Immunol 136: 3324– 3328.
98. Sakatsume M, Igarashi K, Winestock KD, Garotta G, Larner AC, Finbloom DS. 1995. The Jak kinases differentially associate with the α and β (accessory factor) chains of the interferon γ receptor to form a functional receptor unit capable of activating STAT transcription factors. J Biol Chem 270: 17528–17534.
99. Schindler C, Darnell JE. 1995. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem 64: 621–651.
100. Schoenborn JR, Wilson CB. 2007. Regulation of interferon-γ during innate and adaptive immune responses. Adv Immunol 96: 41–101.
101. Schreiber RD, Hicks LJ, Celada A, Buchmeier NA, Gray PW. 1985. Monoclonal antibodies to murine γ-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol 134: 1609–1618.
102. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. 2001. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107–1111.
103. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. 2017. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168: 707–723.
104. Sica A, Bronte V. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155–1166.
105. Sica A, Mantovani A. 2012. Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 122: 787–795.
106. Sica A, Dorman L, Viggiano V, Cippitelli M, Ghosh P, Rice N, Young HA. 1997. Interaction of NF-κB and NFAT with the interferon-γ promoter. J Biol Chem 272: 30412–30420.
107. Siegel JP. 1988. Effects of interferon-γ on the activation of human T lymphocytes. Cell Immunol 111: 461–472.
108. Smith HR, Idris AH, Yokoyama WM. 2001. Murine natural killer cell activation receptors. Immunol Rev 181: 115– 125.
109. Snapper CM, Paul WE. 1987. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236: 944–947.
110. Snapper CM, Peschel C, Paul WE. 1988. IFN-γ stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J Immunol 140: 2121–2127.
111. Snapper CM, Peçanha LM, Levine AD, Mond JJ. 1991. IgE class switching is critically dependent upon the nature of the B cell activator, in addition to the presence of IL-4. J Immunol 147: 1163–1170.
112. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, et al. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387: 917–921.
113. Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang Z-E, Gapin L, Kronenberg M, Locksley RM. 2003. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 198: 1069– 1076.
114. Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, et al. 2017. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 356: 200–205.
115. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. 1988. Interferon-γ: The major mediator of resistance against Toxoplasma gondii. Science 240: 516–518.
116. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655–669.
117. Tanner JW, Chen W, Young RL, Longmore GD, Shaw AS. 1995. The conserved box 1 motif of cytokine receptors is required for association with JAK kinases. J Biol Chem 270: 6523–6530.
118. Tassi I, Colonna M. 2005. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cγ signaling pathways in human NK cells. J Immunol 175: 7996–8002.
119. Tassi I, Presti R, Kim S, Yokoyama WM, Gilfillan S, Colonna M. 2005. Phospholipase C-γ 2 is a critical signaling mediator for murine NK cell activating receptors. J Immunol 175: 749–754.
120. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMil-ler TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. 2012. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 127ra37.
121. Teng MWL, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ. 2012. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 72: 3987–3996.
122. Trent JM, Olson S, Lawn RM. 1982. Chromosomal localization of human leukocyte, fibroblast, and immune interferon genes by means of in situ hybridization. Proc Natl Acad Sci 79: 7809–7813.
123. Tripp CS, Wolf SF, Unanue ER. 1993. Interleukin 12 and tumor necrosis factor α are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci 90: 3725– 3729.
124. Verdegaal EME, de Miranda NFCC, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, et al. 2016. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536: 91–95.
125. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. 2011. Natural, innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235–271.
126. Wallach D. 2017. The tumor necrosis factor family: Family conventions and private idiosyncrasies. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a028431.
127. Walter MR, Windsor WT, Nagabhushan TL, Lundell DJ, Lunn CA, Zauodny PJ, Narula SK. 1995. Crystal structure of a complex between interferon-γ and its soluble high-affinity receptor. Nature 376: 230–235.
128. Wang LL, Yokoyama WM. 1998. Regulation of mouse NK cells by structurally divergent inhibitory receptors. Curr Top Microbiol Immunol 230: 3–13.
129. Wen Z, Zhong Z, Darnell JE. 1995. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241–250.
130. Wolf PR, Ploegh HL. 1995. How MHC class II molecules acquire peptide cargo: Biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol 11: 267–306.
131. + T cells: Evidence for two distinct pathways for promoter activation. Eur J Immunol 29: 548–555.
132. York IA, Rock KL. 1996. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14: 369–396.
133. You M, Yu DH, Feng GS. 1999. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 19: 2416–2424.
134. Young HA, Komschlies KL, Ciccarone V, Beckwith M, Rosenberg M, Jenkins NA, Copeland NG, Durum SK. 1989. Expression of human IFN-γ genomic DNA in transgenic mice. J Immunol 143: 2389–2394.
135. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. 2016. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375: 819–829.
136. Zavodny PJ, Petro ME, Chiang TR, Narula SK, Leibowitz PJ. 1988. Alterations of the amino terminus of murine interferon-γ: Expression and biological activity. J Interferon Res 8: 483–494.
137. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JE. 1996. Two contact regions between Stat1 and CBP/p300 in interferon γ signaling. Proc Natl Acad Sci 93: 15092–15096.
138. Zhang Y, Apilado R, Coleman J, Ben-Sasson S, Tsang S, Hu-Li J, Paul WE, Huang H. 2001. Interferon γ stabilizes the T helper cell type 1 phenotype. J Exp Med 194: 165–172.
139. Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, Bicker A, Lindemann M, Roesch A, Gaudernack G, et al. 2016. Melanoma lesions independently acquire T-cell resistance during metastatic latency. Cancer Res 76: 4347–4358.